

Recombinant Human IL-2

Catalog Number: 202-IL/CF

)ES		

Source E. coli-derived

Ala21-Thr153, with an N-terminal Met

Accession # P60568

N-terminal Sequence Met

Analysis

Formulation

DATA

Predicted Molecular 15 kDa

Mass

SPECIFICATIONS	
SDS-PAGE	13 kDa, reducing conditions
Activity	Measured in a cell proliferation assay using CTLL-2 mouse cytotoxic T cells. Gearing, A.J.H. and C.B. Bird (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M.J. <i>et al.</i> (eds): IRL Press. 295. The ED ₅₀ for this effect is typically 0.05-0.25 ng/mL. The specific activity of Recombinant Human IL-2 is approximately 2.1 x 10 ⁴ IU/μg, which is calibrated against recombinant human IL-2 WHO International Standard (NIBSC code: 86/500).
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 100 µg/mL in sterile 100 mM Acetic Acid.

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.


Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

3 months, -20 to -70 °C under sterile conditions after reconstitution.



1 μg/lane of Recombinant Human IL-2 was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 13 kDa.



Recombinant Human IL-2 (Catalog # 202-IL/CF) stimulates cell proliferation of the CTLL-2 mouse cytotoxic T cell line. The ED_{50} for this effect is typically 0.05-0.25 ng/mL.

Rev. 2/9/2016 Page 1 of 2





Recombinant Human IL-2

Catalog Number: 202-IL/CF

BACKGROUND

Interleukin-2 (IL-2) is a O-glycosylated, four α -helix bundle cytokine that has potent stimulatory activity for antigen-activated T cells. It is expressed by CD4⁺ and CD8⁺ T cells, $\gamma\delta$ T cells, β Cells, dendritic cells, and eosinophils (1-3). Mature human IL-2 shares 56% and 66% as sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit cross-species activity (4). The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes (5-7). The 55 kDa IL-2 R α is specific for IL-2 and binds with low affinity. The 75 kDa IL-2 R β , which is also a component of the IL-15 receptor, binds IL-2 with intermediate affinity. The 64 kDa common gamma chain γ C/IL-2 R γ , which is shared with the receptors for IL-4, -7, -9, -15, and -21, does not independently interact with IL-2. Upon ligand binding, signal transduction is performed by both IL-2 R β and γ C. IL-2 is best known for its autocrine and paracrine activity on T cells. It drives resting T cells to proliferate and induces IL-2 and IL-2 R α synthesis (1, 2). It contributes to T cell homeostasis by promoting the Fas-induced death of naïve CD4⁺ T cells but not activated CD4⁺ memory lymphocytes (8). IL-2 plays a central role in the expansion and maintenance of regulatory T cells, although it inhibits the development of Th17 polarized cells (9-11). Thus, IL-2 may be a key cytokine in the natural suppression of autoimmunity (12, 13).

References:

- 1. Ma, A. et al. (2006) Annu. Rev. Immunol. 24:657.
- Gaffen, S.L. and K.D. Liu (2004) Cytokine 28:109.
- 3. Taniguchi, T. et al. (1983) Nature 302:305.
- 4. Mosmann, T.R. et al. (1987) J. Immunol. 138:1813.
- Liparoto, S.F. et al. (2002) Biochemistry 41:2543.
- 6. Wang, X. et al. (2005) Science 310:1159.
- 7. Bodnar, A. et al. (2008) Immunol. Lett. 116:117.
- 8. Jaleco, S. et al. (2003) J. Immunol. 171:61.
- 9. Malek, T.R. (2003) J. Leukoc. Biol. 74:961.
- Laurence, A. et al. (2007) Immunity 26:371.
 Kryczek, I. et al. (2007) J. Immunol. 178:67:
- Kryczek, I. *et al.* (2007) J. Immunol. **178**:6730.
 Afzali, B. *et al.* (2007) Clin. Exp. Immunol. **148**:32.
- 13. Fehervari, Z. et al. (2006) Trends Immunol. 27:109.